Disclosures for "Safety, Tolerability, And Efficacy Of NE3107 From A Phase 2, Double-Blind, Placebo-Controlled Study In Levodopa/Carbidopa-Treated Patients With Parkinson's Disease")
-
Mr. Ahlem has received personal compensation for serving as an employee of Biovie, Inc.. Mr. Ahlem has received personal compensation in the range of $100,000-$499,999 for serving as an officer or member of the Board of Directors for Biovie, Inc.. Mr. Ahlem has received intellectual property interests from a discovery or technology relating to health care.
-
Dr. Reading has received personal compensation for serving as an employee of Biovie, Inc.. Dr. Reading has received intellectual property interests from a discovery or technology relating to health care.
-
Mr. Djan has received personal compensation for serving as an employee of BioVie Inc..
-
Dr. Palumbo has received personal compensation for serving as an employee of BioVie. An immediate family member of Dr. Palumbo has received personal compensation for serving as an employee of Merck Research Laboratories. Dr. Palumbo has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for BioVie. Dr. Palumbo has stock in BioVie. An immediate family member of Dr. Palumbo has stock in Merck Research Laboratories. Dr. Palumbo has received intellectual property interests from a discovery or technology relating to health care. Dr. Palumbo has received intellectual property interests from a discovery or technology relating to health care. Dr. Palumbo has received intellectual property interests from a discovery or technology relating to health care.